April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Prospective Trial of Botulinum Toxin (Botox&reg) to Control Post-Operative Pain in Eye Enucleation and Evisceration Surgeries
Author Affiliations & Notes
  • J. Schonfeld
    New England Retina Associates, Hamden, Connecticut
  • K. Keyhani
    New York Eye and Ear Infirmary, New York, New York
  • M. Ashenhurst
    Ophthalmology, University of Calgary, Calgary, Alberta, Canada
  • J. McWhae
    Ophthalmology, University of Calgary, Calgary, Alberta, Canada
  • M. Deschênes
    Ophthalmology, Rockyview General Hospital, Calgary, Alberta, Canada
  • Footnotes
    Commercial Relationships  J. Schonfeld, None; K. Keyhani, None; M. Ashenhurst, None; J. McWhae, None; M. Deschênes, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 6405. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Schonfeld, K. Keyhani, M. Ashenhurst, J. McWhae, M. Deschênes; Prospective Trial of Botulinum Toxin (Botox&reg) to Control Post-Operative Pain in Eye Enucleation and Evisceration Surgeries. Invest. Ophthalmol. Vis. Sci. 2010;51(13):6405.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Introduction: : Prospective Trial of Botulinum Toxin (Botox®) to Control Post-Operative Pain in Eye Enucleation and Evisceration Surgeries

Purpose: : To investigate the analgesic efficacy of Botox® (botulinum toxin type A) in controlling post-operative pain following eye enucleation and evisceration surgeries.

Methods: : Adult patients scheduled for first-time enucleation or evisceration surgery were recruited over a two-year period and randomized in a double-blinded fashion to receive Botox or saline (placebo) injections at the time of surgery. The four recti muscles once exposed were injected with either 5 units of 0.1 mL Botox or an equivalent volume of saline as placebo. A standardized post-operative analgesic/narcotic regimen was given as needed.A 10-point numerical ranking scale was used to measure patients’ subjective experiences of pain and nausea, with 0 being no pain/nausea and 10 being the "worst [pain/nausea] imaginable." Pain and nausea were measured pre-operatively, 2-3 hours from the block time in the recovery room; 8-9 hours from the block time, then daily for one week, weekly for one month and bi-weekly for two months for a total of three months' study time.

Results: : Patients who received Botox injection at the time of surgery, as compared to placebo, reported significantly decreased pain levels intraoperatively (mean pain level of 0.27 in treatment group compared to 1.7 in placebo group.) This effect was observed at 8-9 hours from the time of the block. Thereafter, pain scale ratings were similar from POD 1-Week 2 among the two groups. In both groups, there was no reported pain after Week 3. The post-operative narcotic requirement was roughly halved in the treatment group. Antiemetic requirement was reduced by 30% in the treatment arm. In addition, all patients in the placebo group were admitted post-operatively, whereas 3/14 patients in the treatment group were discharged home on the day of surgery.

Conclusions: : Patients who received intramuscular injections of Botox as compared to placebo reported significantly decreased pain levels intraoperatively lasting until 8-9 hours from the time of the block. Post-operative narcotic requirement was decreased by 50% in the treatment arm, and antiemetic requirement was decreased by 30%. Intraoperative use of Botox may offer a great potential for post-operative analgesia and possibly reduce or eliminate post-operative drug regimen and length of hospital stay.

Clinical Trial: : www.eyesite.ca/ 1715-3360

Keywords: wound healing • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×